India’s price new controls on cardiac stents are not a welcome sign
15-Mar-17, ET Healthworld
India's decision to control prices of cardiac stents shows it is a country that isn't business-friendly, according to the US government.
The addition of stents to India's National List of Essential Medicines is contrary to international regulatory norms, said the US Embassy in New Delhi. The products have been made subject to regulation as pharmaceuticals rather than as medical devices.
%20Hindustan%20Times.jpg "Indias price new controls on cardiac stents are not a welcome sign (c) Hindustan Times")
Image: Hindustan Times
“These types of actions send a worrisome signal that India is not in fact fully open for business. Worse, however well-intended the action, this may ultimately result in limiting patients' access to the latest technologies," said George Sibley, acting deputy chief of mission at the US Embassy.